108
Participants
Start Date
December 31, 2008
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
tigecycline
An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
tigecycline
An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
imipenem/cilastatin
Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
Pfizer Investigational Site, Taipei
Pfizer Investigational Site, Taipei TOC
Pfizer Investigational Site, Tainan City
Pfizer Investigational Site, Riga
Pfizer Investigational Site, La Plata
Pfizer Investigational Site, Vác
Pfizer Investigational Site, Victoria
Pfizer Investigational Site, Debrecen
Pfizer Investigational Site, Nyíregyháza
Pfizer Investigational Site, Nambour
Pfizer Investigational Site, Székesfehérvár
Pfizer Investigational Site, Zagreb
Pfizer Investigational Site, Morgantown
Pfizer Investigational Site, Omaha
Pfizer Investigational Site, Argenteuil
Pfizer Investigational Site, Moscow
Pfizer Investigational Site, Moscow
Pfizer Investigational Site, Vsevolozhsk
Pfizer Investigational Site, Saint Petersburg
Pfizer Investigational Site, Saint Petersburg
Pfizer Investigational Site, Novosibirsk
Pfizer Investigational Site, Louisville
Pfizer Investigational Site, Godoy Cruz
Pfizer Investigational Site, Provincia de Buenos Aires
Pfizer Investigational Site, Santiago
Pfizer Investigational Site, Medellín
Pfizer Investigational Site, Bogotá
Pfizer Investigational Site, Tainan City
Pfizer Investigational Site, La Plata
Pfizer Investigational Site, Belo Horizonte
Pfizer Investigational Site, Porto Alegre
Pfizer Investigational Site, São José do Rio Preto
Pfizer Investigational Site, Chicoutimi
Pfizer Investigational Site, Trois-Rivières
Pfizer Investigational Site, Daugavpils
Pfizer Investigational Site, Riga
Pfizer Investigational Site, Seoul
Pfizer Investigational Site, Seoul
Pfizer Investigational Site, Seoul
Pfizer Investigational Site, Seoul
Lead Sponsor
Pfizer
INDUSTRY